П

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| Check this box if no longer subject to |
|--|
| Section 16. Form 4 or Form 5 |
| obligations may continue. See |
| Instruction 1(b). |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB APPROVAL | | | | | | | | | |
|-----------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | |
| Estimated average bur | den | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | |

| 1. Name and Address of Reporting Person* | | | 2. Issuer Name and Ticker or Trading Symbol Blueprint Medicines Corp [BPMC] | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | |
|--|-------------|------------------------|---|-------------------|--|------------------|--|--|--|--|
| Rowland Charles A Jr | | | | X | Director | 10% Owner | | | | |
| | | | | _ | Officer (give title | Other (specify | | | | |
| (Last) | (First) | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 06/20/2019 | | below) | below) | | | | |
| C/O BLUEPR | INT MEDICIN | VES CORPORATION | 00/20/2019 | | | | | | | |
| 45 SIDNEY S | TREET | | | | | | | | | |
| | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Indiv Line) | vidual or Joint/Group Filing (Check Applicable | | | | | |
| (Street) | | | | X | Form filed by One Re | porting Person | | | | |
| CAMBRIDGE | E MA | 02139 | _ | | Form filed by More th Person | an One Reporting | | | | |
| (City) | (State) | (Zip) | | | | | | | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | | | | | | 5. Amount of Securities Beneficially Owned Following Reported | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership |
|---------------------------------|--|---|------|---|--------|---------------|-------------------------------|---|---|---|
| | | | Code | v | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | (Instr. 4) |
| Common Stock | 06/20/2019 | | М | | 11,818 | A | \$9.46 | 11,818 | D | |
| Common Stock | 06/20/2019 | | S | | 947 | D | \$96.69 ⁽¹⁾ | 10,871 | D | |
| Common Stock | 06/20/2019 | | S | | 1,600 | D | \$96.08 ⁽²⁾ | 9,271 | D | |
| Common Stock | 06/20/2019 | | S | | 9,271 | D | \$94.83 ⁽³⁾ | 0 | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | of | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---|---|--|---|------------------------------|---|-----|--------|--|--------------------|---|--|---|--|--|--|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Stock Option (Right to Buy) | \$9.46 | 06/20/2019 | | М | | | 11,818 | (4) | 03/22/2025 | Common Stock | 11,818 | \$0 | 10,000 | D | |

Explanation of Responses:

1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$96.29 to \$97.25 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (3) of this Form 4.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$96.00 to \$96.25 per share.

3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$94.63 to \$94.89 per share.

4. This option was granted on March 22, 2015. This option vested with respect to 1/36th of the shares underlying the option on April 16, 2015 and vested as to an additional 1/36th of the shares underlying the option each month thereafter.

/s/ Christopher Frankenfield, Attorney-in-Fact

06/24/2019

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.